Loading...
Targeted therapeutics — Bruton tyrosine kinase inhibitors (BTKi), anti-CD20 monoclonal antibodies, and the BCL2 inhibitor venetoclax — have become the mainstays of treatment for chronic lymphocytic leukemia (CLL). To investigate the combination of the BTKi ibrutinib plus venetoclax (Ibr/Ven) versus fludarabine, cyclophosphamide, and rituximab (FCR), investigators in the U.K. conducted a multicenter, open-label, partially industry-funded, phase 3 trial in 523 patients with previously untreated CLL.
In the Ibr/Ven group, the duration of treatment was determined by measurable residual disease (MRD) assessed by multiparameter flow cytometry in peripheral blood and bone marrow (maximum treatment, 6 years). Patients with >20% del(17p) were exclude…